Along with other companies, 5AM Ventures (which Scott M. Rocklage is a founding and managing partner of), has been helping finance Expansion Therapeutics’ Series A financing for fighting genetic disorders, such as myotonic dystrophy type 1, the leading cause of muscular dystrophy in adults. Expansion Therapeutics focuses on creating medications that intervene in illnesses that are caused by excessive or defective RNA. 5AM Ventures is a life-science based business that focuses on helping fund companies that are producing treatments for medical needs that as of yet do not have a solution. The name is inspired by the fact that Rocklage’s company helps other companies at an early stage to solve problems.
Scott Rocklage graduated from University of California, Berkley, with a B.S. in chemistry, and earned a Ph.D. in chemistry from the Massachusetts Institute of Technology. He has over three decades of healthcare management experience, having overseen the process that led to the FDA approval of three different drugs. He also has either invented or co-invented more than 30 patents and has published more than 100 peer-reviewed publications.
Rocklage is a chairman at Expansion Therapeutics and has held many significant positions that have prepared him for his current position at 5AM Ventures. He was the President and CEO of Nycomed Salutar, the executive chairman of Relypsa, the chairman and CEO at Cubist Pharmaceuticals, and an executive chairman at EntreMed. He has also held board and advisory roles at eleven organizations, such as Achaogen, Whitehead Organization for Biomedical Research, VBI Vaccines, and WaveRX.
When it comes to Scott Rocklage’s secrets for success, he says that measured risk-taking is very important. It can lead to great developments in business, and can also improve the lives of many people – for example, the individuals who benefit from the medicines that 5AM Ventures has helped fund the development of. Rocklage also says that his organizational skills have helped him be successful. In the future, Rocklage is excited regarding the explosive development of medicine that can treat specific mutations and genotypes. This is a unique method of treating cancer that will only improve in the future.
Connect with Dr. Scott Rocklage on LinkedIn.